scholarly journals Observation of the Improvement in Nocturnal Asthma Symptoms with Administration of Once Daily Sustained Released Theophylline

2018 ◽  
Vol 9 (2) ◽  
pp. 74-77
Author(s):  
Mesbahul Karim Ruble ◽  
AKM Rafiqul Bari ◽  
Amar Biswas ◽  
Md Khairul Anam ◽  
Mahbub E Khuda ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Sustained Release ◽  
Pulmonary Function Tests ◽  
Persistent Asthma ◽  
Nocturnal Asthma ◽  
Once Daily ◽  
Asthma Symptoms ◽  
Sustained Release Theophylline

Objective: The aims and objective of this study to observe the improvement in Nocturnal Asthma symptoms and Quality of Life (QoL) with administration of once daily sustained release theophylline preparation.Background: Nocturnal symptoms are a common part of the asthma. Nocturnal asthma is defined by a drop in forced expiratory volume in 1 second (FEV1) of at least 15% between bedtime and awakening in patients with clinical and physiologic evidence of asthma, which may include improvement in QoL.Methodology: The patient with Chronic Persistent Asthma, both sex, age >18 to 50 years of age and preferably patients with nocturnal exacerbations were included in the study. All patients were diagnosed on the basis of clinical history, physical examination, chest X-ray and pulmonary function tests, in accordance with the clinical criteria for the diagnosis by the GINA. The recruitment period was between March 2017 and August 2017 Shaheed Suhrawardy Medical College Hospital, Dhaka.Results: It was observed that 65(92.85%) was found exacerbation free night and 5(7.15%) patients were found exacerbation with sustained release Theophylline. There are significantly improved qualities of life between 1st follow up to 2nd follow up, 3rd follow up and 4th follow up p<0.001 which was statistically significant. Spirometry test was gradually improved between 1st visit of FEV1 to 2nd, 3rd and 4th visit of FEV1, (p<0.001) that was statistically significant.Conclusion: Most of the patients were found exacerbation free night. There are significantly improved quality of life between 1st follow up to 2nd follow up, 3rd follow up and 4th follow up in Spirometry test. The value of FEV1 was gradually improve in the lst visit, 2nd, 3rd and 4th visit with sustained release Theophylline.J Shaheed Suhrawardy Med Coll, December 2017, Vol.9(2); 74-77

scholarly journals Roxithromycin as Anti-Inflammatory Drug Improves Clinical Outcomes in Adult Patients with Bronchiectasis: A Double- Blinded Randomized, Placebo-Controlled Pilot Clinical Trial

2019 ◽  
Author(s):  
Siwasak Juthong ◽  
Sarayuth Eiamsa-ard
Keyword(s):  
Quality Of Life ◽  
Pulmonary Function ◽  
Clinical Outcomes ◽  
Pulmonary Function Tests ◽  
P Value ◽  
Once Daily ◽  
Function Tests ◽  
Symptom Scores ◽  
Double Blinded

Objective: Macrolides are anti-inflammatory agents that have been reported to improve symptoms in bronchiectasis. The objectives of this study were roxithromycin 300 milligrams (mg) once daily for 8 weeks in patients with bronchiectasis improves the symptom scores as the primary outcome, and the pulmonary function tests and quality of life as the secondary outcomes.Material and Methods: This was a randomized double-blinded placebo-controlled trial of roxithromycin or placebo once daily for 8 weeks in patients with bronchiectasis. Symptom scores, pulmonary function tests, St. George’s Respiratory Questionnaire (SGRQ), and sputum culture were done at each visit.Results: Twenty-eight bronchiectasis patients with a mean age of 56 years participated in this study. Fourteen patients were randomized to receive either roxithromycin 300 mg or placebo once daily. Roxithromycin was shown to improve symptom scores (mean difference of symptom scores=–1.66, p-value=0.005) compared with placebo (mean difference of symptom scores=-0.06, p-value=0.94). Quality of life assessed by the SGRQ, significantly improved in the roxithromycin group (p-value=0.012) but not in the placebo group (p-value=0.84). Pulmonary function tests (forced expiratory volume in one second, forced vital capacity, and diffusing lung capacity of the lung for carbon monoxide) did not improve in either group. None of the patients in the roxithromycin group reported any adverse effects.Conclusion: Roxithromycin once daily showed benefits in clinical outcomes such as symptoms and quality of life. Larger studies of the effects of roxithromycin in bronchiectasis with longer follow-up should be done.

scholarly journals Effectiveness and Quality of Life with Montelukast in Asthma – A double-blind randomized control trial

2019 ◽  
Vol 35 (3) ◽  
Author(s):  
Mirza Saif Ullah Baig ◽  
Rashid Ahmed Khan ◽  
Kamran Khan ◽  
Nadeem Rizvi
Keyword(s):  
Quality Of Life ◽  
Placebo Group ◽  
Asthma Control ◽  
Persistent Asthma ◽  
Double Blind ◽  
Once Daily ◽  
The Mean ◽  
Moderate Persistent Asthma

Objective: To determine the role of montelukast – a leukotriene receptor antagonist (LTRA) – in improving the quality of life (QOL) and asthma control of adult patients with mild to moderate persistent asthma. Methods: Randomized, double-blind, placebo-controlled, non-crossover trial was conducted from March 2017 till November 2018 in three hospitals of Karachi and Hyderabad. Adults of age 15 years or more with mild to moderate persistent asthma. Treatment group was administered tablet montelukast 10mg once daily; the other group was given a similar looking placebo; as an adjuvant to the current medication. QOL was assessed with Asthma Quality of Life Questionnaire – Standard (AQLQ-S) before and after the treatment. Asthma control was monitored via Asthma Control Test (ACT). Results: After 4 weeks, the mean ± SD of overall QOL on AQLQ-S improved from 3.74±0.88 to 5.06±0.89 for montelukast group and from 3.58±0.92 to 4.71±0.97 for placebo group (p=0.02). The improvement in sub-domains of symptoms, activity, and emotional functions was not significant; however, the sub-domain “environmental stimuli” significantly improved with 5.06±0.89 for montelukast group and 4.71±0.97 for placebo group (p=0.02). The mean ± SD of ACT, after four weeks, for montelukast group was 18.19±2.91 and for placebo group 17.28±3.36. Only on ACT, Montelukast did not show any statistically insignificant results. Conclusion: The role of montelukast in improving QOL of adult patients with mild to moderate persistent asthma is quite beneficial. It improves patient quality of life. It has the ease of once daily oral administration and also eradicates side effects associated with long-term adherence to steroids. doi: https://doi.org/10.12669/pjms.35.3.42 How to cite this:Baig S, Khan RA, Khan K, Rizvi N. Effectiveness and Quality of Life with Montelukast in Asthma – A double-blind randomized control trial. Pak J Med Sci. 2019;35(3):---------. doi: https://doi.org/10.12669/pjms.35.3.42 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Comparison of Once-Daily Evening Versus Morning Sustained-Release Theophylline Dosing For Nocturnal Asthma

1987 ◽  
Vol 4 (3) ◽  
pp. 409-419 ◽  
Author(s):  
Alain Reinberg ◽  
Francois Pauchet ◽  
Francois Ruff ◽  
Adrienne Gervais ◽  
Michael H. Smolensky ◽  
...  
Keyword(s):  
Sustained Release ◽  
Nocturnal Asthma ◽  
Once Daily ◽  
Sustained Release Theophylline

Impact of smoking on asthma symptoms, healthcare resource use, and quality of life outcomes in adults with persistent asthma

2007 ◽  
Vol 16 (10) ◽  
pp. 1555-1565 ◽  
Author(s):  
Oren Shavit ◽  
Arlene Swern ◽  
Qian Dong ◽  
Kathleen Newcomb ◽  
Vasilisa Sazonov Kocevar ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Resource Use ◽  
Healthcare Resource ◽  
Persistent Asthma ◽  
Healthcare Resource Use ◽  
Life Outcomes ◽  
Asthma Symptoms ◽  
Quality Of Life Outcomes

scholarly journals Cost of persistent asthma in Italy

2016 ◽  
Vol 11 ◽  
Author(s):  
Roberto W. Dal Negro ◽  
Chiara Distante ◽  
Luca Bonadiman ◽  
Paola Turco ◽  
Sergio Iannazzo
Keyword(s):  
Quality Of Life ◽  
Social Impact ◽  
Persistent Asthma ◽  
Forced Expiratory Volume ◽  
Total Annual Cost ◽  
Common Disease ◽  
Healthcare Resources ◽  
The Impact

Background: Asthma is a common disease of the airways with a significant burden for the society and for patients’ quality of life. The Social Impact of Respiratory Integrated Outcomes (SIRIO) study estimated a mean cost of 1,177.40 € per patient/year in Italy, in 2007. The aim of the present study was to update the cost of persistent asthma patients in Italy. Methods: An observational, retrospective, bottom-up analysis was carried out starting from the data base operating in the Lung Unit of the Specialist Medical Centre (CEMS), Verona (Italy), over the period June 2013-December 2015. Patients’ data were recorded over the 12 ± 2 months before the enrollment and during 12 ± 2 months of follow-up. The prospective was the Italian National Health Service and the broad Italian society. Clinical data were measured in terms of forced expiratory volume in 1 s (FEV1%) and number of relapses. Healthcare resources (namely; number of hospitalizations and/or ER admissions; number of visits; drug use and duration, and indirect costs) were recorded. Results: The cohort consisted of 817 patients with persistent asthma of different severity. They had a 42.96% male prevalence; a mean (±SE) age of 49.06 (±0.64) years; a mean 87.47% (±0.81) FEV1% pred. in baseline, and 69.16% of subjects had comorbidities. The mean (±SE) number of relapses was 0.91 (±0.09) per patient/year before the enrolment. After 12 months, FEV1% significantly improved by +6.31% (±0.45) from the corresponding baseline value (p < 0.001). The number of relapses decreased of −0.46 (±0.09) (p < 0.001). The estimated total annual cost per asthmatic patient was 1,183.14 € (±65.79 €) during the 12 months before the enrolment, and 1,290.89 € (±68.74 €) throughout the follow-up. The increase was mostly due to the significantly increased duration of therapeutic strategies. The costs of hospitalization, general practitioner and rescue medications were significantly decreased. Conclusions: The periodic update of cost analysis is a key to monitor the trend of main asthma outcomes and related expenditure over time. It allows to plan the most convenient actions in terms of prevention strategies and effective interventions, with the aim of optimizing the healthcare resources consumption and maximizing the impact on clinical outcomes and patients’ quality of life. The role of an appropriate pharmacological strategy still proves crucial in minimizing asthma morbidity and the corresponding socio-economic impact.

scholarly journals Effectiveness of Naloxegol in Patients With Cancer Pain Suffering From Opioid-Induced Constipation

2021 ◽  
Author(s):  
Antoine Lemaire ◽  
Yoann Pointreau ◽  
Bérengère Narciso ◽  
François-Xavier Piloquet ◽  
Viorica Braniste ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cancer Pain ◽  
Real Life ◽  
Oral Morphine ◽  
Inadequate Response ◽  
Once Daily ◽  
Patients With Cancer ◽  
Pain Patients

Abstract Purpose Naloxegol, an oral once-daily peripherally acting mu-opioid receptor antagonist, is indicated for the treatment of opioid-induced constipation (OIC) with inadequate response to laxative(s), in cancer and non-cancer patients. This study mainly aimed to assess in real-life conditions the efficacy and safety of naloxegol in cancer pain patients, and the evolution of their quality of life. Methods A non-interventional, 4-week follow-up study was conducted in 24 French oncology and pain centers between 2018 and 2019. Eligible patients were aged ≥ 18 years, treated with opioids for cancer-pain, and started naloxegol for OIC with inadequate response to laxatives. The rate of the response to naloxegol (primary criterion) was assessed at W4. The evolution of quality of life was measured using the Patient Assessment of Constipation Quality of Life (PAC-QOL). Results A total of 124 patients were included (mean age: 62 ± 12 years; ECOG ≤ 2: 79%; primary cancer: lung 18%, breast 16%, prostate 11%, head and neck 9%, digestive 9%...; metastatic stage: 80%). At inclusion, the median opioid dosage was 60 mg of oral-morphine or equivalent. At W4, the response rate was 73.4% (95% CI [63.7%-83.2%]) and 62.9% (95% CI [51.5%-74.2%]) of patients had a clinically relevant change in quality of life (decrease in PAC-QOL score ≥ 0.5 point). Adverse events related to naloxegol were reported in 8% of patients (7% with gastrointestinal events; one serious diarrhea). Conclusion This real-world study shows that naloxegol is effective and well tolerated in cancer pain patients with OIC and that their quality of life improves under treatment.

Pain, Quality of Life, and Clinical Outcomes after Robotic Lobectomy

2016 ◽  
Vol 65 (05) ◽  
pp. 344-350 ◽  
Author(s):  
Zahra Mosala Nezhad ◽  
David Kahn ◽  
Arnaud Steyaert ◽  
Alain Poncelet ◽  
Thierry Pieters ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pulmonary Function ◽  
Pulmonary Function Tests ◽  
Pain Interference ◽  
Pain Intensity Score ◽  
Pain Level ◽  
Variable Intensity ◽  
Significant Difference

Background To evaluate pulmonary function, pain, and quality of life at midterm after robotic lobectomy performed in a single institution. Methods Sixty-five consecutive patients underwent robotic thoracic surgery over 32 months using a complete four-arm portal technique. Sixty-one patients underwent lobectomies predominantly for stage I non–small cell lung cancer. Pulmonary function tests were repeated at midterm follow-up. Pain and quality of life were evaluated during the follow-up on a subgroup of 39 patients, excluding the learning period. Results At a mean of 7-month follow-up, there was no significant difference in preoperative and midterm postoperative pulmonary function. A total of 62.5% of the patients reported a variable intensity of discomfort or pain at the surgical site, with a mean pain intensity score of 2.1 ± 1.4. Mean pain interference score were weak (1.8 ± 1.9), with patients with moderate pain reporting significantly higher pain interference scores than those with mild pain (p = 0.0025). Only one patient suffered from neuropathic-like pain. Quality of life was globally favorable and related to the pain level, with a significant interference on the physical component. Conclusion Robotic lobectomy does not appear to have an impact on midterm pulmonary function. Persistent postoperative pain is mild, nonneuropathic-like, with weak interference on daily activities. Quality of life is satisfactory but related to the pain level.

Sign in / Sign up

Export Citation Format

Share Document